Diabetic retinopathy : current pharmacologic treatment and emerging strategies / Michael W. Stewart, MD.
By: Stewart, Michael W.,, autor
Material type:
E-bookPublisher: Singapore : Adis, 2017Description: 1 recurso en línea.ISBN: 9789811035098; 9811035091.Subject: Retinopatía diabética
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RE661.D5 S749 2017 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.20023397 |
Browsing Madrid Digital shelves, Shelving location: Acceso Electrónico (UEM) Close shelf browser (Hides shelf browser)
| RE661.D5 C556 2014 EB Clinical Strategies in the Management of Diabetic Retinopathy : A step-by-step Guide for Ophthalmologists | RE661.D5 M363 2015 EB Managing Diabetic Eye Disease in Clinical Practice | RE661.D5 S636 2015 EB Small-Gauge Vitrectomy for Diabetic Retinopathy | RE661.D5 S749 2017 EB Diabetic retinopathy : current pharmacologic treatment and emerging strategies | RE661.D5 W818 2011 EB Retinopatía diabética : fundamentos | RE661.M3 2011 EB Macular surgery | RE661 .M3 2018 EB Management of Macular Hemorrhage |
1. Diabetes and Diabetic Retinopathy: Overview Of A World-Wide Epidemic -- 2. The Diabetic Retina: Anatomy and Pathophysiology -- 3. Treatment of Diabetic Retinopathy: A Historical Perspective -- 4. Targeting Vascular Endothelial Growth Factor -- 5. Corticosteroids: Targeting Multiple Cytokines and Chemokines -- 6. Current Treatment Recommendations -- 7. Vitreolysis: Targeting the Vitreoretinal Interface -- 8. Investigational Medications -- 9. Safety Considerations of Pharmacotherapy -- 10. Socioeconomic Cost of Diabetic Retinopathy and Therapy.
A well-illustrated and comprehensive analysis of the treatment of diabetic retinopathy, this book covers current treatment options and guidelines, whilst also providing a detailed discussion of emerging therapeutic targets. Existing therapeutic options are covered in depth, with a major focus on anti-vascular endothelial growth factor drugs and sustained release corticosteroids, including a review of trial results supporting current treatment guidelines. The use of agents off-label is also discussed. Controversial topics are discussed in detail with an emphasis on helping the reader make informed decisions, particularly when treating patients for which several treatment approaches may be appropriate because trial data does not clearly define the best option. Emerging therapeutic areas are evaluated, as work continues to identify agents that produce superior morphologic responses and visual acuity gains by targeting other molecules that contribute to diabetic retinopathy. Promising new drugs, targets and delivery systems are identified, and their development analysed.
There are no comments on this title.